Sanofi will buy vaccine maker Dynavax Technologies for $2.2 billion, or $15.50 a share, adding to its adult immunizations. Dynavax stock soared.
Sanofi (SNY) to acquire Dynavax Technologies (DVAX) for $15.50 per share in cash, expanding its presence in adult immunization.
French drugmaker Sanofi has entered into an agreement to acquire U.S. vaccines company Dynavax Technologies Corporation for around $2.2 billion (1.87 billion euros), it said on Wednesday.
The cash deal seeks to strengthen the French drugmaker's immunization portfolio after it suffered setbacks in clinical trials.
Dynavax stockholders to receive $15.50 in cash, a 39% premium to Dynavax closing share price on December 23, 2025 EMERYVILLE, Calif. , Dec. 24, 2025 /PRNewswire/ -- Sanofi announced today that it has
Sanofi to acquire Dynavax, adding a marketed adult hepatitis B vaccine and phase 1/2 shingles candidate to the pipeline Paris, December 24, 2025. Sanofi announced today that it has entered into an agr
Sanofi provides update on tolebrutinib regulatory submission in non-relapsing secondary progressive multiple sclerosis Paris, December 24, 2025. The US Food and Drug Administration (FDA) has issued a
Sanofi's Wayrilz approved in the EU as the first BTK inhibitor to treat immune thrombocytopenia Novel treatment targets BTK through multi-immune modulation to help address the underlying causes of ITP
Sanofi and Regeneron's Dupixent approved in Japan for children aged 6 to 11 years with bronchial asthma Approval based on global phase 3 program in children demonstrating Dupixent significantly reduce
Information concerning the total number of voting rights and shares, provided pursuant to article L. 233-8 II of the Code de commerce (the French Commercial Code) and article 223-16 of the Règlement
Osaic Holdings Inc. boosted its holdings in Sanofi (NASDAQ: SNY) by 17.0% during the undefined quarter, according to the company in its most recent disclosure with the Securities and Exchange Commissi
Trump and nine major pharmaceutical companies struck deals to lower drug prices for cash payers and Medicaid, with over $150 billion pledged for U.S. R&D and manufacturing.
Guru Stock PicksVanguard Health Care Fund has made the following transactions:Reduce in ARGX by 14.38%Sold out in PACSAdd in CLDX by 3.64%New position in PTGXCI
Officials pledge ‘massive savings' as companies agree to offer drugs at prices paid in other wealthy countries
Several of the largest U.S. and European-based drugmakers inked deals with President Donald Trump to voluntarily sell their medications for less, as his administration pushes to link the nation's drug
Click to get the best stock tips daily for free!

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE